Mss4 as an antifungal target
OwnerDavid Haydoninventor
Life of this patent
Estimating the term…
Abstract
The invention provides 1-phosphotidylinositol-4-phosphate 5-kinase (MSS4) as a novel antifungal target, screening methods for MSS4 inhibitors and their use as antifungal compounds, pharmaceutical compositions containing them and their use in medicine.
Claims22
A method of screening or testing for candidate anti-fungal compounds that impair 1-phosphotidylinositol-4-phosphate 5-kinase enzyme (MSS4) function, comprising:
- a) providing fungal MSS4;
- b) providing one or more candidate compounds;
- c) contacting said MSS4 with said one or more candidate compounds;
- and
- d) determining the interaction of the candidate compound with said MSS4.
A modified eukaryotic cell(s) wherein the cell(s) expresses fungal MSS4 under the control of a heterologous promoter.
A pharmaceutical composition comprising a MSS4 inhibitor and a pharmaceutically acceptable carrier.
Candida or Aspergillus MSS4 as a specific target for antifungal compounds.
(canceled)
(canceled)
The method according to claim 18 wherein the fungal infection is a topical, mucosal or systemic fungal infection.
The method according to claim 18 wherein said compound impairs fungal MSS4 function to a greater extent than host MSS4 function.
A method for the treatment or prevention of fungal infections in a host, which comprises administering to the host a therapeutically or prophylactically effective amount of a MSS4 inhibitor.
A method for the treatment or prevention of fungal infections in a subject who is immunosuppressed, which comprises the step of administering to the subject a therapeurtically or prophylactically effective amount of a MSS4 inhibitor.
Dependencies are inferred from the claim text.